Upadacitinib Significantly Improves Vitiligo vs Placebo

The JAK1 inhibitor in development for treating nonsegmental vitiligo was superior to placebo on investigator ratings in two phase 3 trials.
Medscape Medical News

source https://www.medscape.com/viewarticle/upadacitinib-results-significant-improvements-nonsegmental-2026a10009j2?src=rss